Law Offices of Thomas J. Lamb

  • Free Case Evaluation
  • Mesothelioma & Asbestos Diseases
  • Legal Compensation
  • Asbestos Overview
  • Common Questions
  • About Our Firm

Immunotherapy combination maintains OS advantage in malignant pleural mesothelioma

October 28, 2021 By Thomas Lamb

The combination of nivolumab and ipilimumab maintained its survival advantage over chemotherapy with at least 3 years of follow-up among patients with unresectable malignant pleural mesothelioma, according to CheckMate 743 study results.

Researchers observed the benefit of the first-line immunotherapy regimen despite patients having been off therapy for about 1 year. The findings, presented during the virtual ESMO Congress 2021, also showed no new safety signals with nivolumab (Opdivo, Bristol Myers Squibb) plus ipilimumab (Yervoy, Bristol Myers Squibb).

“Mesothelioma has historically been an extremely difficult‐to‐treat cancer, as it forms in the lining of the lungs rather than as a single tumor. It is also an aggressive cancer with poor prognosis and 5‐year survival rates of approximately 10%,” Solange Peters, MD, PhD, of the medical oncology service and chair of thoracic oncology at Lausanne University Hospital in Switzerland, told Healio. “Before the approval of [ nivolumab and ipilimumab ], no new systemic treatment options that could extend survival for patients with this devastating cancer had been available for more than 15 years.”

The randomized phase 3 CheckMate 743 trial included 605 patients with untreated malignant pleural mesothelioma, stratified according to sex and histology (epithelioid vs. non-epithelioid).

Researchers randomly assigned 303 patients to 3 mg/kg nivolumab, a PD-1 inhibitor, every 2 weeks and 1 mg/kg ipilimumab, which targets CTLA-4, every 6 weeks for up to 2 years. The other 302 patients received platinum-based doublet chemotherapy with 75 mg/m2 cisplatin or carboplatin area under the curve 5 plus 500 mg/m2 pemetrexed for six cycles.

As Healio previously reported, patients in the [ nivolumab and ipilimumab ] immunotherapy and chemotherapy groups had similar baseline characteristics, including median age (69 years for both), percentage of men (77% for both) and histology (epithelioid, 76% vs. 75%).

OS served as the primary endpoint, with safety and biomarker assessments as prespecified exploratory endpoints.

Researchers used RNA sequencing to estimate the association of OS with an inflammatory gene expression signature that included CD8A, PD-L1, STAT-1 and LAG-3, and they categorized expression scores as high vs. low in relation to median score. They also evaluated tumor mutational burden and assessed lung immune prognostic index based on lactate dehydrogenase levels and derived neutrophil-to-lymphocyte ratio at baseline using peripheral blood samples.

Results showed the [nivolumab and ipilimumab ] immunotherapy regimen continued to confer an OS benefit compared with chemotherapy after minimum follow-up of 35.5 months (median OS, 18.1 months vs. 14.1 months; HR = 0.73; 95% CI, 0.61-0.87). Researchers reported 3-year OS rates of 23.2% among patients who received [ nivolumab and ipilimumab ] vs. 15.4% among patients who received chemotherapy, and 3-year PFS rates by blinded independent central review of 13.6% vs. 0.8% (median PFS, 6.8 months vs. 7.2 months; HR = 0.92; 95% CI, 0.76-1.11).

“These results are promising, providing further proof of the durability of the outcomes achieved with this combination,” Peters told Healio.

[Article continues at original source]


 Asbestos & Mesothelioma Information

  Asbestos-Mesothelioma Case Evaluation
Free.  Confidential.  No Obligation.

Filed Under: Medicine, Mesothelioma Tagged With: Ipilimumab, malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments, Nivolumab, Opdivo, Yervoy

Do I Have A Possible Case?

If you have a possible asbestos disease or mesothelioma lawsuit, you can get a free, confidential, and no obligation case review from asbestos lawyer Tom Lamb.

Main Navigation Menu

  • Who Was Exposed to Asbestos
  • NC Asbestos Exposure Sites
  • Asbestos-Contaminated Talc
  • Asbestos Diseases
  • Legal Compensation
  • Free Case Evaluation
  • Frequently Asked Questions
  • About Our Law Firm
  • Attorney Tom Lamb
  • Collection of Articles
  • Sitemap

Attorney Tom Lamb

TJL@LambLawOffice.com

Phone: 800-426-9535

Lumina Station, Suite 225
1908 Eastwood Road
Wilmington, North Carolina

Please know that you can use our Quick Contact Form to tell us about your case.

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Website

Lamb Law Office

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Disclaimer and Copyright Notices
  • Sitemap

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.